Literature DB >> 33863542

Cervical spinal cord infarction associated with coronavirus infectious disease (COVID)-19.

Joshua Kahan1, Cameron J Gibson2, Sara B Strauss3, Matthew Bronstein2, Robert J Winchell2, Philip S Barie4, Alan Z Segal5.   

Abstract

Coronavirus disease (COVID-19) has a number of emerging neurological manifestations in addition to pneumonia and respiratory distress. In what follows, we describe a case of a previously healthy young man with severe COVID-19 who subsequently developed an acute flaccid paralysis. Work up revealed a lesion in his cervical spinal cord concerning for spinal infarction or transverse myelitis. He received empiric pulsed steroids without improvement. Taken together, we felt his presentation was most consistent with spinal cord infarction in the setting of critical illness with COVID-19. We believe this is a rare case of spinal cord stroke associated with COVID-19.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  COVID-19; Coronavirus; Hypercoagulable; SAR-CoV-2; Spinal cord infarct

Mesh:

Year:  2021        PMID: 33863542      PMCID: PMC7938747          DOI: 10.1016/j.jocn.2021.02.027

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   2.116


Case report

Coronavirus disease (COVID-19), has variable manifestations in the critical illness phase beyond acute respiratory distress syndrome including neurologic manifestations [1], [2] and a marked hypercoagulable state [3]. Clinical manifestations of the hyper-coagulable state may include venous thromboembolic disease; thrombosis of arterial monitoring and venous dialysis access catheters; and cerebral infarction [4]. Laboratory evaluation often demonstrates elevated pro-inflammatory biomarkers including serum concentrations of C-reactive protein, D-dimer, fibrinogen, and interleukin-6, among others [5], [6]. We report a case of cervical spinal cord infarction and flaccid quadriparesis associated with COVID-19 disease. A 31 year-old male with no known medical history was admitted to a network inpatient facility with eight days of an acute respiratory illness, which was confirmed by reverse transcriptase polymerized chain reaction of a nasal swab sample to be COVID-19. On hospital day (HD) 6, he was intubated for worsening respiratory failure and transferred to our facility the next day. His vital signs upon admission were T 35.6 °C, HR 126 beats/min, BP 147/93 mm Hg, and RR 18 breaths/min. Neurologic examination revealed spontaneous movement of all four extremities, with no focal findings. There were no other abnormalities on physical examination. Laboratory data are shown in Table 1 . Previous undiagnosed diabetes mellitus was identified (hemoglobin A1c, 12.7%). Hypercoagulability was confirmed by rotational thromboelastometry (ROTEM) [7]. Blood cultures and duplex ultrasonography of the lower extremities were normal.
Table 1

Laboratory Values Reflective of Pro-Inflammatory State. HD, Hospital day; ESR, erythrocyte sedimentation rate.

Parameter (normal value)HD 7HD 12
C-reactive protein (<0.9 mg/dL)1.3<0.4
D-dimer (0229 ng/mL)1,952619
ESR (020 mm/hr)6374
Fibrinogen (180400 mg/dL)699348
Interleukin-6 (<5 pg/mL)91643
Lactate dehydrogenase (118230 U/L)618356
Partial thromboplastin time (27.636.6 sec)39.250.0
Prothrombin time (9.912.5 sec)13.211.4
Platelet count (150450 × 103/mL)335265
White blood cell count (3.411.2 × 103/mL)11.59.4
Laboratory Values Reflective of Pro-Inflammatory State. HD, Hospital day; ESR, erythrocyte sedimentation rate. Once admitted to our ICU the patient was started on enoxaparin 80 mg subcutaneously every 12 h for aggressive thromboprophylaxis [8]. Desired anti-coagulation was confirmed by an anti-factor Xa concentration of 0.7 IU/mL (therapeutic range, 0.5–1.0 IU/mL) on HD 9. Over the following four days mechanical ventilation, vasopressor therapy, and sedation were weaned. There was an isolated recorded blood pressure of 60/37 on HD 8, however on detailed chart review this was reversed with increasing vasopressors within moments. Blood pressure was otherwise consistently at target. The patient moved all extremities during daily sedation holidays. On the morning of HD 12 the patient was unable to move his lower extremities and endorsed absent sedation below the nipples. Up to that point, he had maintained oxygen saturation > 90% and was normotensive. Formal neurologic evaluation revealed that cranial nerves were intact except for multirotational nystagmus. Sensation to light touch and pinprick were intact above the nipples, but absent caudally. The sensory level was at the T4 dermatome. Power of the upper extremities was present but diminished bilaterally (bilateral deltoid muscle 2/5, bilateral triceps muscle 2/5, right biceps muscle and wrist extensors 2/5, left biceps muscle and wrist extensors 3/5, bilateral hand grip 1/5). Power of the lower extremities was absent bilaterally (0/5, flaccid paralysis). He was areflexic except for a weak left biceps tendon reflex. Plantar responses were mute. Clonus was absent. Using the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI), the upper extremity motor sub-score was 17/50, lower extremity motor sub-score was 0/50, sensory sub-scores were 44/112, and the American Spinal Injury Association Impairment Scale was A. Additional serum laboratory values included elevated beta-2 microglobulin (2.6 mg/L; normal range, 1.2–2.4 mg/L), normal immunoglobulin A (227 mg/dL; normal range 85–499 mg/dL), normal ganglioside Gm1 antibody (IgG) (5 IU; normal range 0–50 IU) and ganglioside Gm1 antibody (IgM) (16 IU; normal range 0–50 IU); aquaporin-4 IgG and myelin oligodendrocyte glycoprotein (MOG) IgG were undetectable. Magnetic resonance imaging (MRI) of the spinal cord with and without gadolinium (Fig. 1 ) revealed pronounced T2 hyperintensity and enhancement of the cervical spinal cord spanning C4 through C6 with corresponding restricted diffusion and patchy enhancement mostly within the central gray matter, highly concerning for acute-to-subacute spinal cord infarction. Intramedullary edema surrounded the area of infarction extending from the cervico-medullary junction, predominantly involving the dorsal columns, and extending caudally to T1, where it involved predominantly the central gray matter. Lumbar puncture and MRI of the brain were not performed acutely in the interest of infection control. Despite negative serology, differential diagnosis also included neuromyelitis optica spectrum disorder, MOG antibody associated demyelination, sarcoidosis or a viral transverse myelitis. Given the possibility of a potentially reversible inflammatory process, the patient received methylprednisolone 1 g daily for 5 days, but without improvement. Considering the clinical course, serologies and imaging, we felt the most likely diagnosis was spinal cord infarction. He required tracheostomy for ventilator dependence and gastrostomy for nutritional support.
Fig. 1

MRI of the cervical spine. (a) Sagittal DWI and (b) ADC demonstrate restricted diffusion extending from C4 through C6. (c) Sagittal T1-weighted imaging with gadolinium and (f) axial T1-weighted imaging with gadolinium demonstrate corresponding stippled enhancement, predominantly within central gray matter. (d) Sagittal STIR and (e) axial T2-weighted imaging demonstrate T2 hyperintensity extending from the cervicomedullary junction to the level of the T1 vertebral body.

MRI of the cervical spine. (a) Sagittal DWI and (b) ADC demonstrate restricted diffusion extending from C4 through C6. (c) Sagittal T1-weighted imaging with gadolinium and (f) axial T1-weighted imaging with gadolinium demonstrate corresponding stippled enhancement, predominantly within central gray matter. (d) Sagittal STIR and (e) axial T2-weighted imaging demonstrate T2 hyperintensity extending from the cervicomedullary junction to the level of the T1 vertebral body. As in sepsis generally, COVID-19 disease is characterized by interactions between inflammatory and coagulation cascades [5], but the hypercoagulable state associated with COVID-19 disease is distinct from the typical hypocoagulable state of bacterial sepsis, which is associated with thrombocytopenia. Therapeutic anticoagulation has been advocated in view of recent observations of pathologic clotting in COVID-19 [9], [10], and a suggestion of a survival benefit for critically ill patients [10]. Neurologic associations with COVID-19 are numerous, including both central and peripheral neurologic symptoms [2], [3], [4]. The distribution of cord injury in this case does not conform to classically described vascular distributions of the anterior or posterior spinal arteries, and instead is in central “watershed” areas. This pattern is usually associated with prolonged hypotension in the setting of cardiac arrest [11]. A case series (n = 60) comparing MRI features of spinal infarcts and inflammatory lesions secondary to neuromyelitis optica spectrum disorder suggest that while anterior cord predominance is more consistent with infarct, of the 39 patients with infarcts, 24 had central cord imaging changes on axial slices [12]. Moreover, longitudinally extensive T2 hyperintensity has been observed in the setting of spinal cord infarction, and is attributed to secondary vasogenic edema can be seen in the brain [13]. Of note, the presence of diffusion restriction is not specific for infarct, and it has been seen with inflammatory etiologies [14]. It should be highlighted that because CSF analysis was not performed due to infection control practices at the time, there remained significant clinical uncertainty to justify a trial of high dose steroids. The lack of clinical improvement following steroids is more suggestive of a cord infarct, but not conclusive. Spinal cord pathology associated with the Covid-19 pandemic has included primary spinal epidural abscesses [15], two published case reports of acute myelitis [16], [17] - both of which showed neurological improvement with high-dose steroids, and two cases of possible infarction [18].

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  17 in total

Review 1.  Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma.

Authors:  Kenichi A Tanaka; Daniel Bolliger; Ratna Vadlamudi; Alastair Nimmo
Journal:  J Cardiothorac Vasc Anesth       Date:  2012-08-03       Impact factor: 2.628

2.  Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China.

Authors:  Ling Mao; Huijuan Jin; Mengdie Wang; Yu Hu; Shengcai Chen; Quanwei He; Jiang Chang; Candong Hong; Yifan Zhou; David Wang; Xiaoping Miao; Yanan Li; Bo Hu
Journal:  JAMA Neurol       Date:  2020-06-01       Impact factor: 18.302

Review 3.  Spinal cord ischemia: practical imaging tips, pearls, and pitfalls.

Authors:  M I Vargas; J Gariani; R Sztajzel; I Barnaure-Nachbar; B M Delattre; K O Lovblad; J-L Dietemann
Journal:  AJNR Am J Neuroradiol       Date:  2014-10-16       Impact factor: 3.825

4.  SARS-CoV-2 can induce brain and spine demyelinating lesions.

Authors:  Luca Zanin; Giorgio Saraceno; Pier Paolo Panciani; Giulia Renisi; Liana Signorini; Karol Migliorati; Marco Maria Fontanella
Journal:  Acta Neurochir (Wien)       Date:  2020-05-04       Impact factor: 2.216

5.  Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19.

Authors:  Ishan Paranjpe; Valentin Fuster; Anuradha Lala; Adam J Russak; Benjamin S Glicksberg; Matthew A Levin; Alexander W Charney; Jagat Narula; Zahi A Fayad; Emilia Bagiella; Shan Zhao; Girish N Nadkarni
Journal:  J Am Coll Cardiol       Date:  2020-05-06       Impact factor: 24.094

6.  Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.

Authors:  Thomas J Oxley; J Mocco; Shahram Majidi; Christopher P Kellner; Hazem Shoirah; I Paul Singh; Reade A De Leacy; Tomoyoshi Shigematsu; Travis R Ladner; Kurt A Yaeger; Maryna Skliut; Jesse Weinberger; Neha S Dangayach; Joshua B Bederson; Stanley Tuhrim; Johanna T Fifi
Journal:  N Engl J Med       Date:  2020-04-28       Impact factor: 91.245

7.  Clinical Characteristics of Coronavirus Disease 2019 in China.

Authors:  Wei-Jie Guan; Zheng-Yi Ni; Yu Hu; Wen-Hua Liang; Chun-Quan Ou; Jian-Xing He; Lei Liu; Hong Shan; Chun-Liang Lei; David S C Hui; Bin Du; Lan-Juan Li; Guang Zeng; Kwok-Yung Yuen; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Ping-Yan Chen; Jie Xiang; Shi-Yue Li; Jin-Lin Wang; Zi-Jing Liang; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Nan-Shan Zhong
Journal:  N Engl J Med       Date:  2020-02-28       Impact factor: 91.245

8.  Spinal epidural abscess in COVID-19 patients.

Authors:  G Talamonti; Davide Colistra; Francesco Crisà; Marco Cenzato; Pietro Giorgi; Giuseppe D'Aliberti
Journal:  J Neurol       Date:  2020-09-10       Impact factor: 4.849

9.  Central nervous system manifestations of COVID-19: A systematic review.

Authors:  Ali A Asadi-Pooya; Leila Simani
Journal:  J Neurol Sci       Date:  2020-04-11       Impact factor: 3.181

10.  COVID-19 and its implications for thrombosis and anticoagulation.

Authors:  Jean M Connors; Jerrold H Levy
Journal:  Blood       Date:  2020-06-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.